Ver­sant backs a re­boot­ed Tarve­da with $30M round for pipeline de­vel­op­ment

Just a year af­ter rais­ing $38 mil­lion to re­boot his com­pa­ny, Tarve­da Ther­a­peu­tics CEO Drew Fromkin has hauled in a $30 mil­lion round to fund …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.